Displaying drugs 8351 - 8375 of 9224 in total
Reparixin
Reparixin has been used in trials studying the treatment and prevention of Breast Cancer, Metastatic Breast Cancer, Pancreatectomy for Chronic Pancreatitis, Islet Transplantation in Diabetes Mellitus Type 1, and Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus.
Investigational
Flunoxaprofen
Experimental
Sulfaperin
Experimental
Darinaparsin
Investigational
Acetyl hexapeptide-3
Argireline has been used in trials studying the treatment of wrinkles.
Investigational
N,N-dimethylarginine
Asymmetric dimethylarginine (ADMA) is a naturally occurring chemical found in blood plasma. It is a metabolic by-product of continual protein modification processes in the cytoplasm of all human cells which is closely related to L-arginine, a conditionally-essential amino acid. ADMA interferes with L-arginine in the production of nitric oxide, a...
Experimental
Matched Description: … It is a metabolic by-product of continual protein modification processes in the cytoplasm of all human …
L-methionine (R)-S-oxide
Experimental
L-methionine (S)-S-oxide
Experimental
4-Deoxyglucarate
Experimental
2,3-Dihydroxy-Valerianic Acid
Experimental
alpha-Methylleucine
Experimental
D-Isovaline
Experimental
L-Gluconic Acid
Experimental
Fe-Mesopone
Experimental
D-norleucine
An unnatural amino acid that is used experimentally to study protein structure and function. It is structurally similar to METHIONINE, however it does not contain SULFUR.
Experimental
Matched Description: … An unnatural amino acid that is used experimentally to study protein structure and function. …
Pracinostat
Pracinostat is a novel HDAC inhibitor with improved in vivo properties compared to other HDAC inhibitors currently in clinical trials, allowing oral dosing. Data demonstrate that Pracinostat is a potent and effective anti-tumor drug with potential as an oral therapy for a variety of human hematological and solid tumors.
Investigational
Amelubant
Investigational
Talnetant
Talnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several different functions, primarily for irritable bowel syndrome and as a potential antipsychotic drug for the treatment of schizophrenia.
Investigational
Levopropoxyphene
Levopropoxyphene is a stereoisomer of propoxyphene in the form of 2S, 3R enantiomer. It was sold as an antitussive, but it was removed from the market in the 70s. Levopropoxyphene was developed by Lilly and FDA approved on March 21st, 1962. This drug presented different dosages and it was administered...
Withdrawn
Displaying drugs 8351 - 8375 of 9224 in total